Adult GH deficiency throughout lifetime.
It is now accepted that adults with severe GH deficiency (GHD) demonstrate impaired physical and psychological well-being and may benefit from replacement with recombinant human GH. Post-marketing surveillance surveys, such as the Pfizer International Metabolic Database (KIMS), were initially set-up to provide safety data on long-term treatment but have the added benefit of providing ongoing observational data on the effect of GH replacement on body composition, lipid and glucose status, hypertension, bone density and quality of life. These data demonstrate that although GHD has clinical impact at all ages, the individual consequences of this condition may take on greater significance at different stages in life. At all ages, accurate, safe diagnosis and appropriate GH dosing are necessary to provide the individual with the best possible outcome.
Thomas
Julia D J
JD
Department of Endocrinology, St Bartholomew's Hospital, Queen Mary University of London, UK.
Monson
John P
JP
D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001823:Body Composition; D015519:Bone Density; D016208:Databases, Factual; D005260:Female; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000378:metabolism; D007018:Hypopituitarism / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D011788:Quality of Life; D012737:Sex Factors
D015415:Biomarkers; D001786:Blood Glucose; D007328:Insulin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I